Related Experiment Video
Updated: Jun 21, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Wernicke Encephalopathy Associated With Semaglutide Use
Krishna Sheth1, Elizabeth Garza2, Ajith Saju1
1Internal Medicine, Garnet Health Medical Center, Middletown, USA.
Non-alcoholic Wernicke encephalopathy (WE) is rare but can cause neurological symptoms like dysphagia. This case highlights a potential link between semaglutide use and non-alcoholic WE in a patient presenting with these symptoms.
Area of Science:
- Neurology
- Endocrinology
Background:
- Wernicke encephalopathy (WE) is a neurological disorder commonly associated with alcoholism.
- Non-alcoholic WE is a less common but significant cause of neurological dysfunction.
Observation:
- A 37-year-old male presented with acute neurological symptoms including dysphagia, slurred speech, word-finding difficulty, and restricted extraocular movements.
- These symptoms arose in the context of recent semaglutide use.
Findings:
- The patient was diagnosed with non-alcoholic Wernicke encephalopathy.
- This presentation suggests a potential association between semaglutide and the development of non-alcoholic WE.
Implications:
- This case underscores the importance of considering non-alcoholic WE in patients with neurological deficits, even without a history of alcohol abuse.
- Further investigation is warranted to explore the potential link between semaglutide and Wernicke encephalopathy.
More Related Videos
07:30A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Alzheimer's Disease: Treatment
Antiepileptic Drugs: Glutamate Antagonists